These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32553585)

  • 1. Effects of Anti-vitamin k oral anticoagulants on bone and cardiovascular health.
    Marietta M; Coluccio V; Boriani G; Luppi M
    Eur J Intern Med; 2020 Sep; 79():1-11. PubMed ID: 32553585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.
    Namba S; Yamaoka-Tojo M; Kakizaki R; Nemoto T; Fujiyoshi K; Hashikata T; Kitasato L; Hashimoto T; Kameda R; Meguro K; Shimohama T; Tojo T; Ako J
    Heart Vessels; 2017 Aug; 32(8):977-982. PubMed ID: 28233091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent evidence for direct oral anticoagulants in chronic kidney disease.
    Ha JT; Badve SV; Jun M
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):251-261. PubMed ID: 30789840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
    Loo SY; Coulombe J; Dell'Aniello S; Brophy JM; Suissa S; Renoux C
    BMJ Open; 2018 Jan; 8(1):e019638. PubMed ID: 29371284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease.
    Rogula S; Gąsecka A; Mazurek T; Navarese EP; Szarpak Ł; Filipiak KJ
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis.
    Gupta S; Um KJ; Pandey A; McIntyre WF; Ivanova M; Allahverdi Y; Agahi P; Pandya F; Lopez A; Sachdeva A; Whitlock RP; Belley-Cote EP
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):339-352. PubMed ID: 31011880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
    Yoshihisa A; Sato Y; Sato T; Suzuki S; Oikawa M; Takeishi Y
    BMC Cardiovasc Disord; 2018 Jan; 18(1):11. PubMed ID: 29368593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.
    Hirschl M; Kundi M
    Vasa; 2019 Mar; 48(2):134-147. PubMed ID: 30376416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy and oral anticoagulation in kidney transplant recipients: Direct oral anticoagulants versus vitamin-k antagonists.
    Santoro F; Casanova A; Simone S; Alfieri C; Falcone A; Dello Strologo A; Grandinetti V; Busutti M; Comai G; Marvulli TM; Zippo MG; Castellano G; La Manna G; Gesualdo L; Giuseppe G; Pesce F
    Eur J Intern Med; 2024 Jan; 119():71-77. PubMed ID: 37573220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
    Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
    Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
    Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
    Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Warfarin and Direct Oral Anticoagulants on Systemic Vascular Calcification: A Review.
    Elango K; Javaid A; Khetarpal BK; Ramalingam S; Kolandaivel KP; Gunasekaran K; Ahsan C
    Cells; 2021 Mar; 10(4):. PubMed ID: 33807457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.